LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 39 filers reported holding LYRA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $914,952 | +36.0% | 234,003 | +43.0% | 0.02% | +46.7% |
| Q2 2023 | $672,704 | +863.9% | 163,675 | +371.4% | 0.02% | +1400.0% |
| Q1 2023 | $69,789 | -36.0% | 34,721 | 0.0% | 0.00% | -66.7% |
| Q4 2022 | $109,024 | -37.3% | 34,721 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $174,000 | -19.8% | 34,721 | -9.5% | 0.00% | -33.3% |
| Q2 2022 | $217,000 | +40.0% | 38,374 | -0.4% | 0.01% | +50.0% |
| Q1 2022 | $155,000 | -7.7% | 38,516 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $168,000 | -53.1% | 38,516 | -1.7% | 0.00% | -60.0% |
| Q3 2021 | $358,000 | -46.4% | 39,200 | -52.9% | 0.01% | -52.4% |
| Q2 2021 | $668,000 | -31.1% | 83,155 | -0.6% | 0.02% | -41.7% |
| Q1 2021 | $970,000 | -2.6% | 83,650 | -4.2% | 0.04% | -2.7% |
| Q4 2020 | $996,000 | +104.1% | 87,353 | +100.1% | 0.04% | +23.3% |
| Q3 2020 | $488,000 | – | 43,664 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $5,580,568 | 1.20% |
| Perceptive Advisors | 9,146,730 | $28,720,732 | 0.81% |
| VR Adviser, LLC | 924,170 | $2,901,894 | 0.49% |
| Nantahala Capital Management | 2,220,830 | $6,973,406 | 0.45% |
| PURA VIDA INVESTMENTS, LLC | 2,157,298 | $6,773,916 | 0.35% |
| Soleus Capital Management, L.P. | 592,417 | $1,860,189 | 0.27% |
| Ikarian Capital, LLC | 343,685 | $1,079,171 | 0.26% |
| Clearline Capital LP | 119,128 | $374,062 | 0.07% |
| Anson Funds Management LP | 39,127 | $122,859 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $460,952 | 0.01% |